Irit Gliko-Kabir
Chief Tech/Sci/R&D Officer bei BIOLINERX LTD.
Profil
Irit Gliko-Kabir is currently working as the Vice President-Clinical Operations at BioLineRx Ltd.
She started this position in 2021.
Previously, she worked as the Senior Director-Clinical Development at Bioblast Pharma Ltd.
Dr. Gliko-Kabir has an educational background, having obtained undergraduate, graduate, and doctorate degrees from The Hebrew University of Jerusalem.
Aktive Positionen von Irit Gliko-Kabir
| Unternehmen | Position | Beginn |
|---|---|---|
| BIOLINERX LTD. | Chief Tech/Sci/R&D Officer | 01.09.2017 |
Ehemalige bekannte Positionen von Irit Gliko-Kabir
| Unternehmen | Position | Ende |
|---|---|---|
Bioblast Pharma Ltd.
 Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Irit Gliko-Kabir
| The Hebrew University of Jerusalem | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BIOLINERX LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
